Canaccord initiated coverage of Structure Therapeutics (GPCR) with a Buy rating and $101 price target
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GPCR:
- Kailera Stock (KLRA) Rockets 68% after IPO in Race for $150B Obesity Market
- Structure Therapeutics Appoints Matthew Lang as Chief Operating Officer
- Structure Therapeutics appoints Matthew Lang as COO
- Buy Rating on GPCR Driven by Competitive Aleniglipron Phase 2b Efficacy and Clear Path to Phase 3 in Obesity
- Structure Therapeutics price target lowered to $100 from $114 at H.C. Wainwright